← Browse by Condition
Medical Condition

primary peritoneal carcinoma

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for primary peritoneal carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — primary peritoneal carcinoma Clinical Trials

How many clinical trials are currently recruiting for primary peritoneal carcinoma?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for primary peritoneal carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for primary peritoneal carcinoma?
primary peritoneal carcinoma research spans Phase 1 (3 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a primary peritoneal carcinoma clinical trial?
Eligibility criteria for primary peritoneal carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
3
Phase 2
2
Top Sponsors
Regeneron Pharmaceuticals 1 trial
Beijing Biotech 1 trial
Genmab 1 trial

Recruiting Clinical Trials

NCT06469281 Phase 1
Recruiting
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Enrollment
90 pts
Location
United States
Sponsor
Regeneron Pharmaceuticals
View Trial →
NCT07480954 Phase 1, Phase 2
Recruiting
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Enrollment
36 pts
Location
China
Sponsor
Beijing Biotech
View Trial →
NCT05579366 Phase 1, Phase 2
Recruiting
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Enrollment
884 pts
Location
United States, China...
Sponsor
Genmab
View Trial →

Related Conditions

epithelial ovarian cancer (2) fallopian tube cancer (2) fallopian tube carcinoma (1) recurrent or refractory disease after standard therapies (1) high grade epithelial ovarian cancer (1) high grade serous ovarian cancer (1) endometrial cancer (1) non small cell lung cancer (1) epidermal growth factor receptor egfr mutated non small cell lung cancer nsclc (1) mesothelioma (1) breast adenocarcinoma (1) triple negative breast cancer (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology